- Conditions
- Sickle Cell Disease, Vaso-Occlusive Crisis
- Interventions
- Ketamine
- Drug
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Oakland, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 72
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Inclacumab, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
- Conditions
- Vaso-occlusive Crisis, Sickle Cell Disease
- Interventions
- Saline, MST-188
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Oakland, California + 43 more
- Conditions
- Vaso-occlusive Crisis, Sickle Cell Anemia Crisis
- Interventions
- hyperbaric oxygen therapy
- Device
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Sickle Cell Disease
- Interventions
- Sham 2D Headset Control, Passive Immersive 3D Virtual Reality, Active Immersive Interactive 3D Virtual Reality
- Device
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Vaso-occlusive Crisis
- Interventions
- Ketamine Hydrochloride
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anemia, Sickle Cell
- Interventions
- Arginine, Placebo
- Drug
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 17
- States / cities
- Oakland, California • San Francisco, California • Denver, Colorado + 10 more
- Conditions
- Anemia; Sickle-Cell, With Crisis, Acute Pain
- Interventions
- Ketamine, Pain management
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Virtual Reality Therapy
- Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee
- Conditions
- Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Nirmish Shah
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Sickle Cell Disease, Thalassemia
- Interventions
- Etavopivat tablets
- Drug
- Lead sponsor
- Forma Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 14
- States / cities
- Cerritos, California • Los Angeles, California • Oakland, California + 9 more
- Conditions
- Sickle Cell Disease
- Interventions
- Gabapentin, Placebo
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 20 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Sickle Cell Disease Vaso-occlusive Crisis
- Interventions
- CSL889, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Oakland, California • Orange, California • Fort Myers, Florida + 14 more
- Conditions
- Sickle Cell Crisis
- Interventions
- Ketamine, Normal Saline
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Providence, Rhode Island
- Conditions
- Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)
- Interventions
- Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm)
- Drug · Other
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Sickle Cell Anemia
- Interventions
- L-NMMA, Sodium Nitrite
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode
- Interventions
- L-citrulline, Placebo
- Drug · Other
- Lead sponsor
- Suvankar Majumdar
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Sickle Cell Disease
- Interventions
- MST-188
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 9
- States / cities
- San Diego, California • Fort Myers, Florida • Hollywood, Florida + 6 more
- Conditions
- Hemoglobin SC Disease
- Interventions
- Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid
- Drug · Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more
- Conditions
- Sickle Cell Anemia Crisis
- Interventions
- Acetaminophen, Normal saline
- Drug
- Lead sponsor
- Newark Beth Israel Medical Center
- Other
- Eligibility
- 4 Years to 16 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Newark, New York
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Placebo, Dalteparin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Sickle Cell Disease (SCD)
- Interventions
- Crizanlizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 9 more
- Conditions
- Sickle Cell Disease
- Interventions
- Anumigilimab, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Orange, California • Hollywood, Florida + 6 more
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis, Vaso-Occlusive Crises
- Interventions
- Comprehensive Care Plan
- Other
- Lead sponsor
- Valley Anesthesiology Consultants
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona